Low battery
Battery level is below 20%. Connect charger soon.
Stream iconic series, movies, reality, live sports, and more from hbo, discovery, warner bros, cartoon network, and adult swim. If you get hbo with your tv package, internet service, or wireless plan, you may have access to hbo max at no extra cost. · an experimental pfizer drug for sickle cell disease failed to meet its goal in a phase 3 study, the company said friday. · pfizers phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned. · pfizers inclacumab fails to show efficacy in treating sickle cell anemia in a late-stage clinical trial, marking another setback after oxbryta withdrawal. Sign in to access hbo max, the streaming platform with movies, series, and exclusive max originals. · in a recent development that has sent ripples through the medical and pharmaceutical communities, pfizer announced the failure of its phase 3 clinical trial for … Say hello to hbo max, the streaming platform that bundles all of hbo together with even more of your favorite movies and tv series, plus new max originals. By padmanabhan ananthan (reuters) -in the latest setback for pfizers sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for … It’s the latest setback for pfizer in … · (reuters) -pfizer’s experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said on friday. To find out if your provider supports hbo max, go to ways to get … The trial tested … Testing showed that treatment with inclacumab, a drug pfizer … · pfizers inclacumab fails phase iii study for sickle cell disease, disappointing the community while the company remains committed to future treatments. Enrollment in a phase 3 study is currently paused due … · a pfizer drug designed to address a severe problem associated with sickle cell disease failed to beat a placebo in a phase 3 clinical trial. · thrive-131 trial, pfizer’s latest late-stage study of inclacumab in people with sickle cell disease (scd), has concluded without meeting its primary endpoint. · pfizer is evaluating a separate experimental therapy, osivelotor, as a potential chronic treatment for sickle cell disease. Results showed no significant … Analysis of the impact on …
